ARID1A and cancer: However, significantly improved PFS or prolonged stable disease was achieved in certain groups of patients, such as patients with ARID1A-deficient OCCC or PTPRB-mutated STS, suggesting that ENMD-2076 may have clinical benefit in these molecular subtypes of cancer.